In China, Rare Dissent Over a Program to Save on Drug Costsnews2025-01-25T05:00:05+00:00January 25th, 2025|The New York Times|
Man Charged With Giving Fake Botox Injections That Sickened Clientsnews2025-01-22T23:30:04+00:00January 22nd, 2025|The New York Times|
Chinese startup begins first clinical trial using CRISPR to edit cells directly in the bone marrownews2025-01-22T20:02:34+00:00January 22nd, 2025|Endpoints News|
Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharmanews2025-01-22T10:48:58+00:00January 22nd, 2025|Endpoints News|
China’s drug development explosion forces a US biotech reckoningnews2025-01-21T15:30:24+00:00January 21st, 2025|Endpoints News|
Ascentage estimates $133M in proceeds as it plans dual listingnews2025-01-21T15:11:16+00:00January 21st, 2025|Endpoints News|
Another US biotech emerges with drug candidate from China-based Keymednews2025-01-20T11:48:36+00:00January 20th, 2025|Endpoints News|
The embryo editing debate is back, revived by Nature articlenews2025-01-12T17:21:58+00:00January 12th, 2025|Endpoints News|
Lawmakers ask administration to tighten China trial rulesnews2025-01-10T20:03:11+00:00January 10th, 2025|Endpoints News|
Four biotechs emerge with $800M and in-licensed assets on Fridaynews2025-01-10T15:04:37+00:00January 10th, 2025|Endpoints News|
